← All stocks

NEKTAR THERAPEUTICS

NKTR Net selling
CIK 0000906709 #1869 in the set updated 18 Sep 2026
Bought (120 mo)
$1.38M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$212.36M
$2.99M on a plan · $161.30M straight out of an exercise
Sold at will
$48.07M
212 of 362 sales
Net
−$210.98M
−$46.69M against sales at will

By person

22 insiders · 387 transactions
3.5×

Howard W. Robin holds only 3.5 times base salary in stock. $3.96M of shares against $1.11M in salary for 2025.

Salary from the company's own proxy. The shares are what Howard W. Robin last reported holding, valued at $71.98, the price Common Stock was last bought or sold at on the open market here, on 18 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
ROBIN HOWARD W
President & CEO
$72.66M (92) scheduled
−$72.66M
55,037
$3.96M
Doberstein Stephen K
SVP & Chief Scientific Officer
$259.20K (1)
$30.70M (17) scheduled
−$30.45M
107,668
$7.75M
+468.6%
Nicholson John
SVP & Chief Operating Officer
$29.63M (17)
−$29.63M
162,759
$11.72M
+33.4%
Labrucherie Gil M
SVP, COO & CFO
$23.30M (44) scheduled
−$23.30M
312,905
$22.52M
+471.5%
Thomsen Jillian B.
Chief Financial Officer
$8.79M (29) scheduled
−$8.79M
313,497
$22.57M
+546.0%
Hora Maninder
SVP Pharma Dev & Mfg Ops
$8.41M (15) scheduled
−$8.41M
94,694
$6.82M
+75.5%
CHESS ROBERT
Director
$7.40M (31) scheduled
−$7.40M
259,473
$18.68M
−16.2%
KUEBLER CHRISTOPHER A
Director
$6.08M (5) scheduled
−$6.08M
45,250
$3.26M
+64.5%
Lingnau Lutz
Director
$5.23M (8) scheduled
−$5.23M
35,800
$2.58M
+59.5%
Zalevsky Jonathan
Chief R&D Officer
$4.92M (39)
−$4.92M
9,570
$688.85K
Gergel Ivan P.
SVP & Chief Medical Officer
$4.62M (9) scheduled
−$4.62M
56,553
$4.07M
+106.9%
GREER R SCOTT
Director
$202.50K (1)
$4.42M (5) scheduled
−$4.22M
303,574
$21.85M
+208.7%
WINGER DENNIS L
Director
$3.87M (4)
−$3.87M
47,750
$3.44M
+52.8%
WHITFIELD ROY A
Director
$918.46K (4)
$17.10K (1) scheduled
+$901.36K
287,750
$20.71M
+475.5%
NORTHCOTT JOHN
SVP & Chief Commercial Officer
$691.58K (6)
−$691.58K
223,210
$16.07M
Wilson Mark Andrew
Chief Legal Officer
$673.71K (26)
−$673.71K
21,585
$1.55M
Ajer Jeffrey Robert
Director
$653.48K (8)
−$653.48K
34,153
$2.46M
Curet Myriam
Director
$109.24K (4)
−$109.24K
27,418
$1.97M
Deep Track Capital, LP entity
10% owner
$99.63K (1)
−$99.63K
18,344,000
$1.32B
−0.3%
EASTHAM KARIN
Director
$76.77K (1)
−$76.77K
23,233
$1.67M
Krivulka Joseph J
Director
82,000
$5.90M
+64.0%
Brainard Diana
Director
28,560
$2.06M

No percentages here. This company's share count has moved by a factor of 9.8 over the window, from 19,018,573 to 186,103,588 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Doberstein Stephen K
5 Sep 2019
SVP & Chief Scientific Officer
Buy
15,000
$17.28
$259.20K
Showing 250 of 387 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 443
Amendments (4/A) skipped 8
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 27
Sales straight out of an exercise 123
Sales at will 212
Transactions with no price 0
Shares from compensation/vesting 10,236,554
Sales filed before the plan box existed 165
History held since 2 Sep 2016